BriaCell Therapeutics Corp. (BCT.TO)
| Previous close | 1.5200 |
| Open | 1.4300 |
| Bid | 1.3000 x N/A |
| Ask | 1.3700 x N/A |
| Day's range | 1.3000 - 1.4300 |
| 52-week range | 1.3000 - 10.1982 |
| Volume | |
| Avg. volume | 8,748 |
| Market cap | 23.77M |
| Beta (5Y monthly) | 1.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5100 |
| Earnings date | 14 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireBriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patientsTherapy well-tolerated with no Bria-IMT™ related discontinuationsClinical data highlight significant potential of Bria-IMT™ in advanced metastatic breast cancerSuperiority of selected Phase 3 regimen and formulation confirmedOral presentation by Mayo Clinic Profe
GlobeNewswireBriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces initiation of a first-in-human, Phase 1/2 study evaluating safety and efficacy of Bria-OTS™, BriaCell’s personalized off-the-shelf next generation immunotherapy, as monotherapy and in combination with PD-1 inhibitor ti
- GlobeNewswire
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASD
